Strokes and A Fib are side effects of COVID Shots
COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes Claire Rogers 1,*, James A Thorp 2,3, Kirstin Cosgrove 4 and Peter A McCullough 5
https://www.ijirms.in/index.php/ijirms/article/view/1982
This study used data from CDC, FDA, and VAERS databases from 1990 through 2023. It compared reports of Adverse Events after COVID shots compared to those after influenza vaccines and to all other vaccines. It did this by using Proportional Reporting Ratio (PRR). PRRs are a statistical measure to help detect whether a specific adverse event from one drug is reported more often compared to another. It is commonly used to identify potential safety signals. A PRR of 1 means the Adverse Event was reported at the same rate for both drugs. A PRR of 2 means the Adverse Event was reported twice as often in the subject drug compared to the comparison drug. Indeed, a PRR of 2 is the usual cut off to trigger a safety signal.
Cerebral Venous Thrombosis was reported 2000 times more often after COVID shots compared to influenza vaccinations (PRR 2070: 95% CI, 955-4490, p < 0.0001).
Cerebral Arterial Thrombosis was reported 1000 times more often after COVID shots compared to influenza vaccinations (PRR 1120: 95% CI, 152-8280, p < 0.0001).
Total Cerebral Thrombosis was reported 1000 times more often after COVID shots compared to influenza vaccinations (PRR 1120: 95% CI, 723-1730, p < 0.0001).
Atrial fibrillation was reported 100 times more often after COVID shots compared to all other vaccines (PRR 123: (95% CI, 88.3-172, p << 0.0001).
Further, the “Pfizer post-marketing analysis done from December 10, 2020 to February 28, 2021 [documented] 42,086 casualties including 1223 deaths in just the first 10 weeks of rollout.”*
*BNT162b2 5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021. Report prepared by Worldwide Safety Pfizer for the Federal Drug Administration and approved on April 30, 2021.https://phmpt.org/wp- content/uploads/2021/11/5.3.6-postmarketing-experience.pdf. (Accessed June 15, 2023).
By the way, this 10 week analysis is part of the Pfizer data that the FDA requested to stay sealed for 75 years. Well, they lost that lawsuit and in January 2022 a federal judge ruled that the FDA must expedite the release of these documents.